• Innate Pharma filed its 2025 universal registration document, outlining a sharper focus on three lead clinical programs: IPH4502, lacutamab, monalizumab.
• Strategy shift announced in September 2025 redirected spending toward those assets, with preclinical work narrowed to advancing next ADC candidates.
• Restructuring cut headcount by about 30%, with planned layoffs expected to conclude in April 2026.
• Lecutamab advanced with FDA Breakthrough Therapy designation in February 2025, with Phase 3 TELLOMAK-3 targeted for second-half 2026, subject to securing non-dilutive funding.
• Monalizumab partner AstraZeneca completed enrollment in Phase 3 PACIFIC-9, with data expected in second-half 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.